Sonja Brune
Nurse Practitioner · San Antonio, TXNPI 1780683888
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,800 of the $50,998 with a category attached, or 62.4%. 24 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 48.9% of the total. Reporting peaked in 2022 at $15,585 and has fallen 64.6% since, to $5,522 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $260.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$25K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21K
- Abbott$2K
- Boston Scientific$1K
- Merck$327
- Novo Nordisk$282
- plus $2K from 18 others
What the payments were for
- Consulting fees$6,25012%
- Speaking & faculty fees$31,80062%
- Travel & lodging$4,94310%
- Food & beverage$8,00516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 43 | $24,926 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 38 | $20,523 |
| Abbott | 26 | $1,842 |
| Boston Scientific | 21 | $1,055 |
| Merck | 12 | $327 |
| Novo Nordisk | 5 | $282 |
| E.r. Squibb & Sons, L.L.C. | 7 | $275 |
| Actelion Pharmaceuticals US, Inc. | 5 | $260 |
| Medtronic | 2 | $216 |
| Cvrx, Inc. | 6 | $208 |
| Amgen | 4 | $196 |
| Abiomed | 1 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Irhythm Technologies, Inc. | 4 | $116 |
| Johnson & Johnson | 3 | $107 |
| Novartis | 5 | $104 |
| AstraZeneca | 1 | $101 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 3 | $41 |
| Bayer | 2 | $34 |
| Pfizer | 1 | $19 |
| Itamar Medical Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$35,052
- LifeVest$19,925
- OPTIMIZER SMART SYSTEM$6,250
- CARDIOMEMS$807
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$296
- Ozempic$247
- CAMZYOS$237
- Repatha$141
- Impella$128
- Watchman$122
- CoreValve Evolut$121
- UPTRAVI$116
- OPSUMIT$116
- Barostim Neo System$111
- VERQUVO$100
How this compares
$50,998 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $310,622 |
| FarxigaDapagliflozin Propanediol | 73 | $60,951 |
| EntrestoSacubitril/Valsartan | 18 | $32,345 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,359 |
| Spironolactone | 87 | $1,034 |
| Ranolazine ErRanolazine | 16 | $934 |
| Metoprolol Succinate | 61 | $739 |
| Bumetanide | 12 | $709 |
| Carvedilol | 64 | $698 |
| Torsemide | 28 | $680 |
| Digoxin | 24 | $521 |
| Eplerenone | 12 | $497 |
| Potassium Chloride | 16 | $401 |
| Furosemide | 51 | $372 |
| Fluticasone Propionate | 17 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $19 | $310,62214 claims |
| AstraZenecaFarxiga | $101 | $60,95173 claims |
| NovartisEntresto | $104 | $32,34518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in San Antonio
- Corrie BerkSan Antonio$155K
- Laura GalvanSan Antonio$32K
- Eduardo GonzalezSan Antonio$32K
- Roberta RomeroSan Antonio$26K
- Christopher GarciaSan Antonio$21K
- Jennifer ZavalaSan Antonio$17K
- Amy RivasSan Antonio$17K
- Alexis WahlenSan Antonio$16K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.